secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2025-06-24T23:59:59+00:00
Accession:  0001193125-25-145405
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics raises $15M via registered direct offering of 3.2M shares at $4.67
--------------------------------------------------------------------------------

- Gross proceeds ~$15M from sale of 3,221,395 shares at $4.67/share; closing expected June 25, 2025.
- Purchasers include existing healthcare-focused institutional investors, executive officers, and directors.
- Net proceeds to support pre-commercialization and launch readiness for CAN-2409 in prostate cancer; BLA submission planned Q4 2026.
- Insider participation signals confidence in Candel's strategy and pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000119312525145405/0001193125-25-145405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000119312525145405/d34398d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-145405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer